Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma

Tuo Zhang(Shanghai Jiao Tong University), Beibei Sun(Shanghai Jiao Tong University), Chenxi Zhong(Shanghai Chest Hospital), Ke Xu(Shanghai Chest Hospital), Zhexin Wang(Shanghai Chest Hospital), Paul Hofman(Hôpital Pasteur), Tatsuya Nagano(Kobe University), Antoine Legras(Université de Tours), Daniel Breadner(London Health Sciences Centre), Biagio Ricciuti(Dana-Farber Cancer Institute), Duilio Divisi(University of L'Aquila), Ralph A. Schmid(University of Bern), Ren‐Wang Peng(Shanghai Jiao Tong University), Haitang Yang(Shanghai Chest Hospital), Feng Yao(Shanghai Jiao Tong University)
Translational Lung Cancer Research
April 1, 2021
Cited by 88Open Access
Full Text

Abstract

Background: Intrinsic or acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is common, thus strategies for the management of EGFR-TKIs resistance are urgently required. Ferroptosis is a recently discovered form of cell death that has been implicated in tumorigenesis and resistance treatment. Accumulating evidence suggests that ferroptosis can be therapeutically exploited for the treatment of solid tumors; however, whether ferroptosis can be targeted to treat EGFR mutant lung cancer and/or overcome the resistance to EGFR-TKIs is still unknown.Methods: The effect of ferroptosis inducers on a panel of EGFR mutant lung cancer cell lines, including those with EGFR-TKI intrinsic and acquired (generated by long-term exposure to the third-generation EGFR-TKI osimertinib), was determined using cytotoxicity assays. Further, drug candidates to enhance the effect of ferroptosis inducers were screened through implementing WGCNA (weighted gene co-expression network analysis) and CMAP (connectivity map) analysis. Flow cytometry-based apoptosis and lipid hydroperoxides measurement were used to evaluate the cell fates after treatment.Results: Compared with EGFR-TKI-sensitive cells, those with intrinsic or acquired resistance to EGFR-TKI display high sensitivity to ferroptosis inducers. In addition, Vorinostat, a clinically used inhibitor targeting histone deacetylase, can robustly enhance the efficacy of ferroptosis inducers, leading to a dramatic increase of hydroperoxides in EGFR mutant lung cancer cells with intrinsic or acquired resistance to EGFR-TKI. Mechanistically, Vorinostat promotes ferroptosis via xCT downregulation.Conclusions: Ferroptosis-inducing therapy shows promise in EGFR-activating mutant lung cancer cells that display intrinsic or acquired resistance to EGFR-TKI. Histone deacetylase inhibitor (HDACi) Vorinostat can further promote ferroptosis by inhibiting xCT expression.


Related Papers

No related papers found

Powered by citation graph analysis